Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Global Orthobiologics Market To Post 5.9% CAGR To 2019 As Limitations Of Autografts And Allografts Come To Fore

|Includes: Meridian Resource Corp. (TMR)

The current set of limitations associated with autografts and allografts will help turn the spotlight on orthobiologics in the coming years. As a result of this, the global orthobiologics market will post a CAGR of 5.9% from 2013 to 2019, says a recent study by Transparency Market Research. The study reveals that while the global orthobiologics market stood at US$3,745.6 million in 2012, it will rise to touch US$5,519.9 million in 2019. Orthobiologics will be chiefly employed in the treatment of bone injuries and osteoarthritis, the projections state. These findings are detailed in the report titled "Orthobiologics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019."

Get Report Sample and Customize: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1747

Orthobiologics help expedite tissue and skeletal healing. Musculoskeletal procedures showing an upward trend in recent years have acted as the biggest driver for the global orthobiologics market. In contrast, the greatest restraint for the market's growth will be in the form of lack of clear reimbursement policies and rigorous regulations. The report studies the global orthobiologics market on the basis of product type, application, and geography. Using product type as a criteria, the report segments the orthobiologics market into bone morphogenetic proteins, demineralized bone matrix (DBM), synthetic bone substitutes, viscosupplementation, allograft, stem cell therapy, and machined bones. According to the report, the viscosupplementation segment stood as the largest in the global orthobiologics market because of a high demand for knee treatment procedures. Viscosupplementation is regarded as being a more effective pain killer than NSAIDS. The BMPs market was the second largest in 2012, but will fall from its current position to register negative growth because of a nosedive in the sales of Medtronic's INFUSE.

Patients and medical practitioners are now more interested in opting for stem-cell-based products and synthetic bone substitutes. This makes the stem cell therapy segment in the orthobiologics market a strong contender; TMR analysts expect this segment to log the fastest rate of growth in the next few years. Likewise, orthobiologics applications studied in the report are spinal fusion, trauma, and reconstructive surgery. The market also offers a regional analysis of the orthobiologics market by segmenting it this: North America, Asia Pacific, Europe, and Rest of the World. Of these, North America and Europe are currently the dominant regions in the global orthobiologics market because of a high prevalence of obesity and arthritis here. This has consequently created a massive demand for minimally invasive procedures, which include growth factor treatments and bone grafting. During the remainder of the forecast period, the Asia Pacific region will show the highest rate of growth as a result of an expanding geriatric population base, more sports injuries and accidents being reported, and the adoption of a more sedentary lifestyle.

The competitive landscape of the global orthobiologics market is composed of players such as Bacterin International, Inc., Alphatec Spine, Inc., DePuy Synthes, Inc., Biomet, Inc., Globus Medical, Inc., Exactech, Inc., Medtronic, Inc., Integra LifeSciences Corporation, Zimmer Holdings, Inc., and others.